Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
about
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shockStreptococcal necrotising fasciitis from diverse strains of Streptococcus pyogenes in tropical northern Australia: case series and comparison with the literatureThe Production Processes and Biological Effects of Intravenous ImmunoglobulinUse of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.Management and Novel Adjuncts of Necrotizing Soft Tissue Infections.Intravenous immunoglobulin for treating sepsis and septic shock.Antibodies against a surface protein of Streptococcus pyogenes promote a pathological inflammatory response.Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study.Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodiesInvasive group A streptococcal disease: Management and chemoprophylaxisChimeric anti-staphylococcal enterotoxin B antibodies and lovastatin act synergistically to provide in vivo protection against lethal doses of SEB.Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis.Managing toxic shock syndrome with antibiotics.Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Practice guidelines for the diagnosis and management of skin and soft-tissue infections.World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infectionsegc-Encoded superantigens from Staphylococcus aureus are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxinNew insights into the prevention of staphylococcal infections and toxic shock syndrome.Late multiple organ surge in interferon-regulated target genes characterizes staphylococcal enterotoxin B lethality.The Japanese guidelines for the management of sepsis.Clinical and microbiologic characteristics of invasive Streptococcus pyogenes infections in north and south India.Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndromeNecrotizing fasciitis: pathogenesis and treatment.Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulinTherapies for necrotising fasciitis.Emerging drugs for the treatment of sepsis.Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspectiveIntravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis.Streptococcus pyogenes and re-emergence of scarlet fever as a public health problem.Bacterial, fungal, parasitic, and viral myositisTherapeutic considerations for children with invasive group a streptococcal infections: a case series report and review of the literature.Refractory Toxic Shock-Like Syndrome from Streptococcus dysgalactiae ssp. equisimilis and Intravenous Immunoglobulin as Salvage Therapy: A Case SeriesCase 1: Pneumonia with hypotension and a rash.Intravenous immunoglobulin in children with streptococcal toxic shock syndrome.Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.Mesenchymal stromal (stem) cells suppress pro-inflammatory cytokine production but fail to improve survival in experimental staphylococcal toxic shock syndrome.Streptococcal Toxic Shock Syndrome Caused by Group G Streptococcus, United Kingdom.HMGB1 in severe soft tissue infections caused by Streptococcus pyogenesAgents to reduce cytokine storm.
P2860
Q24198059-682FE5B6-C22F-4541-8671-675AB4945256Q24799782-EB3D3E45-AD2E-47C6-A98D-F884B04E994BQ26752540-F46F64BB-0D79-4730-9EEF-42A14DA46437Q30145641-726BF2E5-78E0-479C-9F82-1DD1FFCB45CEQ30234954-7952D461-BCA5-4316-823B-6A8186A946B0Q30820719-85ADE17E-5811-4BD4-91CC-D82CA0BAB29AQ33369063-D37634ED-2760-47B6-9F59-DA4FB7466164Q33719201-FB1A2BA9-E146-4A8D-AB67-FF65EA623C2DQ33753208-D6E28074-A78F-4477-AF49-9122855D8E06Q33877190-C0CD9CC1-DB1A-40A8-895F-07289170F228Q34030444-824CB632-03F1-43A2-BCA9-D0078C95A1AFQ34079264-3605D94D-A648-4693-B7B1-BBE83250C2E7Q34123551-CE8BCCBA-2939-4E4A-8762-A2F491B62DB3Q34334680-E5531E20-328C-4B90-8E91-5C5B8F78E358Q34413457-F7E7A119-635A-4C6B-BBC6-3042D161339BQ34460523-64376246-831D-4E78-B7B2-665BC2094C58Q34565950-AC6AEC79-58EA-425D-832D-786B5D038AACQ34761242-75867B84-6787-4A0A-A1C0-325280922A91Q35008802-1E0C90B2-372B-4F57-8F5C-1FDF2B2C7ECDQ35097527-5BD819D9-9291-46FF-8116-40E25F64C6BCQ35107094-E9740823-ABC6-4E12-ABA9-184274391C98Q35942999-891A8FE2-B925-4972-BBCF-141A2753E040Q36126966-C642CF8A-4D69-4AFA-ABA7-D4FF7B59E713Q36140694-08BCF846-85F5-44BB-9141-FFEF90975D75Q36216880-F52F9ABA-6221-465C-A3B0-1D5CCF098124Q36377217-B4E30085-E878-4D31-A77D-C53F1AAD2550Q36407391-47E4B4AF-1852-4F09-B7A1-3FF9E15475F0Q36646072-9E19EC18-2A8F-4999-9689-B7D02844CE02Q36658182-FDCBFC1E-F343-4FAF-AF06-8F0C0D13D728Q36779701-BF862C2C-9247-497D-8498-B56F342F23E4Q36803883-E293C40E-9675-4FC7-BBFE-FE73714173CAQ36853382-FC7D2030-8448-4F37-B978-30E7C78D2E0AQ37212533-F3E5329B-67EF-48E2-8CC9-CB3A757C0358Q37289345-B5EAF0EA-FB88-4851-9C36-F5E581A132D7Q37387611-0BB7CC0C-19D8-4650-AD2E-F2A979DE7B1FQ37471470-3F2FD89A-03CA-4CF7-9B88-F3448B31B388Q37501623-BFA4DEE5-F580-4B08-87CC-8D767621AAD6Q37524703-6ECB1B22-5F7C-438B-89C7-02D93C86D7D0Q37531146-C8CD9869-570A-4304-999B-70569E75CF5CQ37577684-F8354213-F0DE-4DE6-AED7-B8338BEE0928
P2860
Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Intravenous immunoglobulin G t ...... ind, placebo-controlled trial.
@en
Intravenous immunoglobulin G t ...... ind, placebo-controlled trial.
@nl
type
label
Intravenous immunoglobulin G t ...... ind, placebo-controlled trial.
@en
Intravenous immunoglobulin G t ...... ind, placebo-controlled trial.
@nl
prefLabel
Intravenous immunoglobulin G t ...... ind, placebo-controlled trial.
@en
Intravenous immunoglobulin G t ...... ind, placebo-controlled trial.
@nl
P2093
P2860
P356
P1476
Intravenous immunoglobulin G t ...... ind, placebo-controlled trial.
@en
P2093
Anna Norrby-Teglund
Ewa Aufwerber
Jan Andersson
Jan Sjölin
Jessica Darenberg
Nahla Ihendyane
Per Follin
StreptIg Study Group
Sven Haidl
P2860
P304
P356
10.1086/376630
P407
P577
2003-07-17T00:00:00Z